Vascular endothelial growth factors (VEGF) inhibitors are an example of this, as they are active on tumors relying on VEGF-dependent angiogenesis such as renal cancer (drug-sensitive), but not on tumors sustained by VEGF-independent forms of vessel formation (innate resistance) or tumors recurring after treatment, that present VEGF-independent compensatory programs of neovascularization (acquired resistance). This evidence concerns the gene VEGFA and renal carcinoma.